Determination of Circulating miRNAs as Diagnostic Markers of Lung Disease in Cystic Fibrosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cystic Fibrosis
- Sponsor
- University Hospital, Montpellier
- Enrollment
- 80
- Locations
- 2
- Primary Endpoint
- Comparison of miRNAs expression between Cystic Fibrosis (CF) patients and healthy controls
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients
Detailed Description
The objective of this project is to study the circulating miRNA profiles in 40 patients with cystic fibrosis (5 samples which are acquired through a secondary use) and 40 healthy individuals to assess whether these biomolecules could be used as markers of the pulmonary disease in cystic fifbosis. Moreover by comparing miRNAs expression level between Cystic fibrosis (CF) patients with severe (n=20) or moderate (n=20) pulmonary impairment, we want to assess whether some of these miRNAs may be used as markers for the severity of CF pulmonary disease. The identification of sensitive and early markers, from a non-invasive sampling could enable more effective and early treatment of CF patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Cystic fibrosis (CF) (MIM#219700) who are compound heterozygous or homozygous for CF causing mutations Healthy controls non -smokers and free pulmonary disease
Exclusion Criteria
- •Participation or within the exclusion period of other clinicals trials Patients carrying mutations of clinical varying consequences or non CF-causing mutations
Outcomes
Primary Outcomes
Comparison of miRNAs expression between Cystic Fibrosis (CF) patients and healthy controls
Time Frame: After blood collection: 2 years
Compare the distributions of miRNAs expression in blood samples of CF patients and to healthy controls
Secondary Outcomes
- Assesment of miRNAs expression in Cystic Fibrosis Patients depending on the pulmonary status(After blood collection 2 years)